Plain-English translation of NCT03340129 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether combining two immune therapy medications— and —with a type of focused radiation called stereotactic radiotherapy works better than the medications alone for treating melanoma that has spread to the brain. The study compares patients who receive both the medications and radiation to those who receive just the medications.
When melanoma spreads to the brain, it becomes very serious. Early research suggests that radiation may help the immune system work better against the cancer, but doctors need to confirm whether adding radiation to this medication combination actually improves survival and quality of life for patients.
You likely qualify if…
You likely don't qualify if…
You will have an MRI scan of your brain for planning purposes, then be randomly assigned to one of two groups. Both groups receive the same immune therapy medications given intravenously every 3 weeks for 4 doses, followed by maintenance doses every 4 weeks. One group also receives focused radiation to the brain tumors within a week of the planning scan. You will have regular follow-up visits with brain scans, blood tests, and assessments of your thinking and quality of life over the course of treatment.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
Australia